Inflammatory Bowel Diseases

Skip Navigation LinksHome > February 2014 - Volume 20 - Issue 2 > Endoscopic Balloon Dilatation of Crohn's Disease Strictures:...
Inflammatory Bowel Diseases:
doi: 10.1097/01.MIB.0000439067.76964.53
Original Clinical Articles

Endoscopic Balloon Dilatation of Crohn's Disease Strictures: Results from a Large United Kingdom Series

Bhalme, Mahesh MRCP*; Sarkar, Sanchoy FRCP, PhD; Lal, Simon FRCP, PhD; Bodger, Keith FRCP, MD§,‖; Baker, Rose PhD, FRSS, FIMA, CStat, CMath; Willert, Robert P. FRCP, PhD**

Collapse Box


Introduction: Stricturing is a common complication of Crohn's disease. Endoscopic balloon dilatation (EBD) offers a valuable alternative to surgical intervention, but there are limited data on factors influencing its safety and efficacy.

Methods: A multicenter retrospective audit across 4 U.K. teaching hospitals was performed on the use of EBD for Crohn's strictures between 1998 and 2011. Demographics, smoking status, medications, C-reactive protein, endoscopic findings, and subsequent surgery at follow-up were recorded. Success of EBD was defined as symptomatic improvement without the need for surgery at follow-up.

Results: Seventy-nine patients (47 women; median age, 48 yr) were identified for this study. Forty-eight (61%) patients had ileocolonic anastomotic strictures, whereas the rest had de novo strictures. In total, 191 EBDs (range, 1–11; median 2) were carried out on 93 strictures (range, 1–5; median 1) over a median duration of 12 months (range, 1–84). There were no serious adverse events. Success at index EBD was 34%, with a further 43% achieving long-term benefit from additional EBDs. Eighteen (23%) patients required surgery. Time to surgery after the first EDB was 2.6 to 71.1 months (median, 12.8 mo). Longer Crohn's disease duration (P = 0.03) and high C-reactive protein (P = 0.008) were associated with an increased need for subsequent surgery.

Conclusions: EBD was safe and effective in achieving long-term symptom improvement and avoidance of surgery in most patients. Prospective controlled trials are needed to evaluate the effect of other factors, including Crohn's disease phenotype, and the role of concomitant medication to identify those best suited to EBD.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.